Since 1976, methicillin-resistant Staphylococcus auriieis (MRSA) has been a serious problem in Dublin hospitals (3, 4, 10) as well as in other centers (7, 8, 17, (21) (22) (23) (25) (26) (27) (28) . From 1979 to 1983, approximately 30% of S. alurelus strains isolated from blood cultures taken from patients in our hospitals were MRSA. Initially, we treated severe MRSA infection with a variety of antimicrobial agents other than vancomycin. Since August 1980, we have used vancomycin as the drug of first choice in treating severe MRSA infection. Here we report the results of treatment of MRSA septicemia.
MATERIALS AND METHODS
Patients. The patients involved in this study were in nine Dublin hospitals; the hospitals contained a total of about 3, 000 beds and included all specialties except neurosurgery. The clinical staff took blood cultures from patients with symptoms suggesting bacteremia or septicemia. Septicemia was defined as isolation of an organism from blood cultures on two or more occasions when the symptoms were still present. Detailed clinical records were kept in the laboratories, and the charts were reviewed on recovery and again on discharge or at the time of death.
From 1978 through 1983, there were 48 episodes of MRSA septicemia in 44 patients. In 41 of the episodes, MRSA was in pure culture. In six episodes it was combined with Pseudomonas aerluginosal (three times), Streptococcus sp. (once), Bacteroides sp. (once), and Protelus morganii (once).
One patient developed superinfection with Candida albicans and subsequently had mixed septicemia with MRSA and C. albicans.
Processing of blood culture specimens. Eight of the hospitals were served by a central microbiology laboratory. Blood cultures were incubated at 37°C in the hospital of origin pending transport to the central microbiology laboratory. The other hospital was served by an on-site microbiology * Corresponding author.
laboratory. During the period of study, two systems of blood culture were in operation.
(i) Before August 1982, a conventional system of blood culture processing was used (29) . A 10-ml sample of blood was taken aseptically, and 5 (18) , as it has been suggested that in view of the similar activity, toxicity, and pharmokinetics of the two drugs, the kanamycin nomogram could be used for amikacin (5) . Assay of levels in serum was performed in four patients only, and peak levels were therapeutic.
Vancomycin is a potentially toxic drug (6) . Infusion into a large vein has been reported to reduce the incidence of thrombophlebitis associated with its administration (6, 12 as at weekends), the interdose interval was increased, taking into account the degree of renal failure pending assay of levels in serum.
RESULTS
The patients were divided into three groups on the basis of antibiotic treatment.
(i) Group 1. Patients receiving inadequate therapy. Inadequate therapy included no administration of antimicrobial agent, administration of an agent to which the MRSA isolate was resistant on disk sensitivity testing, or administration of the correct antibiotic in subtherapeutic dosage. This group contained 15 patients, 6 females and 9 males. The age range was 31 to 77 years (mean, 59.5 years). Clinical details are shown in Table 1 . Eleven of these patients died of septicemia after an illness lasting from 6 h to 14 days (mean, 3 days). One patient in this group (no. 14) survived. He presented 6 weeks later with septicemia and mycotic aneurysm of the femoral artery. It was necessary to amputate the leg; the septicemia was successfully treated with vancomycin.
(ii) Group 2. Patients receiving antimicrobial agents, other than vancomycin, to which MRSA was susceptible. This group contained 16 patients, who had 17 episodes of septicemia. These will be considered to be 17 patients for the purpose of this analysis. There were 4 females and 13 males. The age range was 26 to 79 years (mean, 52.8 years). Clinical details are shown in Table 2 . Eight of these patients were treated for up to 72 h with other antimicrobial agents pending results of antimicrobial susceptibility testing. Fourteen patients were treated with amikacin, sometimes in combination with another agent. Seven of these patients (50%) died of uncontrolled infections. One of these seven patients had mixed septicemia with C. albicans terminally, for which amphotericin B was also administered. Two patients (no. 19 and 20) who failed to respond to amikacin were changed to vancomycin therapy. Only 1 of the 14 recovered fully; the remain- Patients were divided into three groups for analysis. There was a predominance of males in all three groups. In group 1, the mean age (59.5 years) was higher than in the other two groups (both with a mean of 52.8 years). The high mortality (94%) in group 1, in which the patients had inadequate therapy or no therapy, indicates the pathogenicity of these strains.
Before mid-1980, we used amikacin as the drug of choice to treat severe MRSA infections, on the basis of results of laboratory susceptibility testing. This drug was occasionally combined with a cephalosporin because of reports of in vitro synergy of such combinations against MRSA (2, 13, 18). The results for group 2 were somewhat better than those in group 1, but only 18% recovered fully. These data are consistent with earlier findings of low efficacy of gentamicin treatment in patients infected with gentamicin-susceptible S. aureus strains (14) . Clearly, aminoglycosides are suboptimal ther-apy of severe staphylococcal infection. In the present study, the dosage of amikacin was based on body weight and renal function; however, serum assay was not performed in the majority of cases. Factors which may be important in treatment failure could be related to low antibiotic levels in serum, the metabolism of the organisms (15, 16) , or possibly an in vitro diffusion block. Another factor that may have an important effect on outcome is the time interval between onset of septicemia and initiation of appropriate antibiotic therapy. Antibiotic susceptibilities were not available until 2 to 4 days after sampling in the majority of patients subsequently treated with amikacin, and initial treatment was with an antimicrobial agent to which the MRSA isolate was resistant in vitro.
Because of the poor results of treatment with other antimicrobial agents, we decided to use vancomycin as the drug of choice for MRSA septicemia in 1980. Of the 18 patients treated with vancomycin (group 3), 14 (72%) made a full recovery. In 13 of the septicemia episodes in group 3, vancomycin therapy was administered within 18 h of the onset of symptoms. A rapid blood culture system and increased awareness of the possibility of MRSA septicemia both contributed to this earlier treatment, which may have influenced the outcome. Of the patients who died, only one (6%) had uncontrolled infection. However, MRSA was usually not eradicated from the carrier sites or the lesions. In three patients, continuing carriage was the probable source of reinfection, which was fatal in one patient. There may be a place for a controlled trial of vancomycin versus vancomycin and rifampin (19 
